Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Edoxaban
Drug ID BADD_D02469
Description Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Indications and Usage Edoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
Marketing Status Not Available
ATC Code B01AF03
DrugBank ID DB09075
KEGG ID D09710
MeSH ID C552171
PubChem ID 10280735
TTD Drug ID D0C3BS
NDC Product Code Not Available
Synonyms edoxaban | N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide | N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)ethanediamide p-toluenesulfonate monohydrate | Savaysa | DU-176 | DU-176b | edoxaban tosylate
Chemical Information
Molecular Formula C24H30ClN7O4S
CAS Registry Number 480449-70-5
SMILES CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000371%Not Available
Abdominal pain07.01.05.0020.000371%
Anaemia01.03.02.0010.000742%
Arthralgia15.01.02.0010.000556%
Asthenia08.01.01.0010.000371%Not Available
Cardiac failure02.05.01.0010.000145%
Cerebrovascular accident24.03.05.001; 17.08.01.0070.000742%
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000371%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.0030.000556%Not Available
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.000742%
Drug hypersensitivity10.01.01.001--Not Available
Dyspnoea22.02.01.004; 02.01.03.0020.000742%
Epistaxis24.07.01.005; 22.04.03.0010.001298%
Faeces discoloured07.01.03.0020.000371%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.001669%Not Available
Gingival bleeding07.09.07.001; 24.07.02.0100.000371%Not Available
Haematuria24.07.01.047; 20.02.01.0060.001484%
Blood urine present13.13.02.0020.000927%Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.0060.000371%Not Available
Headache17.14.01.0010.000556%
Insomnia19.02.01.002; 17.15.03.0020.000556%
Nausea07.01.07.001--
Palpitations02.01.02.0030.000371%
Paraesthesia17.02.06.0050.000371%
Pneumonia22.07.01.003; 11.01.09.0030.000371%Not Available
Rash23.03.13.0010.000927%Not Available
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.000556%
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.0010.000556%
Haemorrhage24.07.01.0020.000742%Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages